- Previous Close
6.81 - Open
6.82 - Bid 6.34 x 100
- Ask 6.62 x 100
- Day's Range
6.33 - 6.93 - 52 Week Range
5.32 - 19.49 - Volume
171,687 - Avg. Volume
150,340 - Market Cap (intraday)
46.395M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-1.59 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.20
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
www.electrocore.comRecent News: ECOR
View MorePerformance Overview: ECOR
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ECOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ECOR
View MoreValuation Measures
Market Cap
46.40M
Enterprise Value
38.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.92
Price/Book (mrq)
6.15
Enterprise Value/Revenue
1.53
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-47.20%
Return on Assets (ttm)
-41.57%
Return on Equity (ttm)
-158.63%
Revenue (ttm)
25.18M
Net Income Avi to Common (ttm)
-11.89M
Diluted EPS (ttm)
-1.59
Balance Sheet and Cash Flow
Total Cash (mrq)
11.97M
Total Debt/Equity (mrq)
54.83%
Levered Free Cash Flow (ttm)
-4.08M